{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:57:08Z","timestamp":1769608628858,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ahj.2017.05.016","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T19:30:18Z","timestamp":1496518218000},"page":"86-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry"],"prefix":"10.1016","volume":"190","author":[{"given":"Marco","family":"Proietti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.E. Juhani","family":"Airaksinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rubboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Schlitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuomas","family":"Kiviniemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasi P.","family":"Karjalainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory YH","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ahj.2017.05.016_bb0005","first-page":"317","article-title":"Atrial Fibrillation and Stroke: Making Sense of Recent Observations on Anticoagulation","volume":"34","author":"Proietti","year":"2016","journal-title":"Cardiol Clin"},{"issue":"6","key":"10.1016\/j.ahj.2017.05.016_bb0010","first-page":"1080","article-title":"The optimal management of patients on oral anticoagulation undergoing coronary artery stenting","volume":"112","author":"Rubboli","year":"2014","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.ahj.2017.05.016_bb0015","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.amjcard.2008.08.021","article-title":"Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy","volume":"102","author":"Rossini","year":"2008","journal-title":"Am J Cardiol"},{"issue":"16","key":"10.1016\/j.ahj.2017.05.016_bb0020","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.ahj.2017.05.016_bb0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ahj.2017.05.016_bb0030","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of cardiology\/American heart association task force on practice guidelines and the heart rhythm society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ahj.2017.05.016_bb0035","first-page":"2719","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Hear J"},{"issue":"45","key":"10.1016\/j.ahj.2017.05.016_bb0040","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ahj.2017.05.016_bb0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.ahj.2017.05.016_bb0050","first-page":"E864","article-title":"The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study","volume":"82","author":"Schlitt","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"issue":"6","key":"10.1016\/j.ahj.2017.05.016_bb0055","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22254","article-title":"One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry","volume":"37","author":"Rubboli","year":"2014","journal-title":"Clin Cardiol"},{"issue":"2","key":"10.1016\/j.ahj.2017.05.016_bb0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ahj.2017.05.016_bb0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.ahj.2017.05.016_bb0070","first-page":"1087","article-title":"Vitamin K antagonists in heart disease: Current status and perspectives (Section III)","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"issue":"22","key":"10.1016\/j.ahj.2017.05.016_bb0075","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","article-title":"Universal definition of myocardial infarction","volume":"116","author":"Thygesen","year":"2007","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ahj.2017.05.016_bb0080","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ahj.2017.05.016_bb0085","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jacc.2015.05.062","article-title":"Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation","volume":"66","author":"Hess","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2017.05.016_bb0090","doi-asserted-by":"crossref","first-page":"e0147245","DOI":"10.1371\/journal.pone.0147245","article-title":"Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","volume":"11","author":"Sambola","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ahj.2017.05.016_bb0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2017.05.016_bb0100","series-title":"Hear Rhythm","first-page":"1581","article-title":"Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study","volume":"13(8)","author":"Chan","year":"2016"},{"issue":"5","key":"10.1016\/j.ahj.2017.05.016_bb0105","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2017.05.016_bb0110","series-title":"Am J Cardiol","first-page":"72","article-title":"Relation of nonvalvular atrial fibrillation to body mass index (from the SPORTIF Trials)","volume":"118(1)","author":"Proietti","year":"2016"},{"key":"10.1016\/j.ahj.2017.05.016_bb0115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ebiom.2016.04.013","article-title":"Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials","volume":"8","author":"Proietti","year":"2016","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.ahj.2017.05.016_bb0120","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1161\/STROKEAHA.116.013173","article-title":"Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin","volume":"47","author":"Senoo","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2017.05.016_bb0125","article-title":"Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in atrial fibrillation patients on warfarin","author":"Senoo","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2017.05.016_bb0130","doi-asserted-by":"crossref","first-page":"24376","DOI":"10.1038\/srep24376","article-title":"Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores","volume":"6","author":"Proietti","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ahj.2017.05.016_bb0135","series-title":"PLoS One","first-page":"e0164076","article-title":"Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry","volume":"11(10)","author":"Haas","year":"2016"},{"issue":"9872","key":"10.1016\/j.ahj.2017.05.016_bb0140","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2017.05.016_bb0145","series-title":"Am Heart J","first-page":"472","article-title":"An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention","volume":"169(4)","author":"Gibson","year":"2015"},{"issue":"25","key":"10.1016\/j.ahj.2017.05.016_bb0150","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2017.05.016_bb0155","first-page":"323","article-title":"Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy","author":"Gibson","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2017.05.016_bb0160","series-title":"Eur Hear J - Cardiovasc Pharmacother","first-page":"191","article-title":"Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel","volume":"1(3)","author":"Rohla","year":"2015"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317301710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317301710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:59:14Z","timestamp":1757570354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870317301710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":32,"alternative-id":["S0002870317301710"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2017.05.016","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2017.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}